
    
      A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC
      that are eligible for resection will be enrolled in this study. All patients will receive one
      dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te
      amount of circulating tumor cells
    
  